Fennec Pharmaceuticals (FENC) Retained Earnings (2010 - 2026)

Fennec Pharmaceuticals (FENC) has 16 years of Retained Earnings data on file, last reported at -$229.4 million in Q4 2025.

• Quarterly Retained Earnings fell 4.43% year-over-year to -$229.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$229.4 million (down 4.43% YoY) and the FY2025 annual result came in at -$229.4 million, down 4.43% from the prior year.
• Retained Earnings declined to -$229.4 million in Q4 2025, from $1.2 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $215.6 million in Q3 2023 to a low of -$229.4 million in Q4 2025.
• A 5-year average of -$65.7 million and a median of $1.2 million in 2022 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings surged 209.81% — and 2024, when it tumbled 17773.45%.
• Tracing FENC's Retained Earnings over 5 years: stood at -$179.5 million in 2021, then soared by 100.69% to $1.2 million in 2022, then changed by 0.0% to $1.2 million in 2023, then plunged by 17773.45% to -$219.7 million in 2024, then decreased by 4.43% to -$229.4 million in 2025.
• The last three Retained Earnings figures came in at -$229.4 million (Q4 2025), $1.2 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.